Was muss ich über Quellen wissen?

Alammar N et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Med Ther 2019. PMC6337770. https://pmc.ncbi.nlm.nih.gov/articles/PMC6337770/ Cannigma Research Team. CBD research: clinical evidence, safety, gaps. https://cannigma.com/research/cbd-research-clinical-evidence-safety-gaps/ Cannabis Regulations AI. EFSA 2025 CBD safety update, Novel Food. https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/efsa-2025-cbd-safety-update-novel-food Cannabis Regulations AI. EU 2025 EFSA Novel Food CBD guidance. https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/eu-2025-efsa-novel-food-cbd-guidance Cannanda. Beta-Caryophyllene BCP overview. https://cannanda.com/en-us/blogs/hemp-guide/the-science-behind-beta-caryophyllene-bcp-and-its-health-benefits Deutsche Apotheker Zeitung. Wenn Cannabinoide wechselwirken. 2020. https://www.deutsche-apotheker-zeitung.de/daz-az/2020/daz-14-2020/wenn-cannabinoide-wechselwirken Drugs.com. History of Epidiolex (FDA approval 25.06.2018). https://www.drugs.com/history/epidiolex.html FDA / PMC. Emerging use of Epidiolex (cannabidiol) in epilepsy. PMC7439947. https://pmc.ncbi.nlm.nih.gov/articles/PMC7439947/ Frontiers Pharmacology 2025. OTC CBD in Germany, market analysis. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1571025/full